February 16: The Week in Cancer News
Researchers explore a try-everything approach to precision medicine, and physical activity may help ease cancer pain.
Progress Against Cancer
Researchers explore a try-everything approach to precision medicine, and physical activity may help ease cancer pain.
The FDA has granted accelerated approval to lifileucel, a new type of cell therapy, for the treatment of melanoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi) for...
The FDA has granted full approval to tepotinib for some non-small cell lung cancers that harbor a certain mutation in the MET gene. The U.S. Food and Drug Administration (FDA) has approved tepotinib (Tepmetko)...
The FDA has approved irinotecan liposome plus chemotherapy for the first-line treatment of metastatic pancreatic cancer. The U.S. Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde), in combination with the chemotherapeutics oxaliplatin,...
Patients and doctors urge researchers to study lower doses for cancer treatments, and the FDA faces criticism for not issuing a formaldehyde ban in hair straighteners.
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...
The FDA expanded the indications for pembrolizumab to include more patients with stage III-IVA cervical cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus chemoradiotherapy (CRT) for the treatment of...
Improving fitness linked to lower prostate cancer risk, and a study from Scotland finds no cervical cancer cases in women vaccinated before age 14.
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More